Trial · NCT00456495
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
NCT00456495, Phase 1, Completed, The New York Eye Cancer Center; results first posted 2013-06-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Ranibizumab on Malignant Conjunctival Neoplasia. Trials, record NCT00456495. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00456495
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Ranibizumab on Malignant Conjunctival Neoplasia
- NCT number
- NCT00456495
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 5 participants, actual
- Lead sponsor
- The New York Eye Cancer Center
- Conditions
- Conjunctival Neoplasms
- Interventions
- ranibizumab
- First posted
- 2007-04-05
- Last updated
- 2017-07-21
- Results first posted
- 2013-06-06
- Limitations and caveats
- This was a small case series involving a small number of subjects. Further investigations for dose, drug delivery and case selection are warranted.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Assessed for Safety and Tolerability | 2 years | To test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia - using comparative slit lamp examination \[anterior segment and ocular adnexal examination for adverse events (eg abrasion, melting), visual acuity (number of patients with decrease in visual acuity), and blood pressure at each visit (number of patients with increased blood pressure from baseline), and monthly urinalyis (number of patients with abnormal protein level in urine). |
| Secondary | Evaluating Tumor Destruction or Reduction | 2 years | To evaluate the efficacy of treatment using comparative slit lamp examinations (anterior segment and ocular adnexal exam) to evaluate tumor volume, from baseline to month 12, and 24. To report on the number of patients with improvement in tumor volume. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Assessed for Safety and Tolerability | 2 years | Analysis was per protocol. Treatment was delivered every 2-4 weeks with good safety and tolerability | participants | NUMBER |
| SECONDARY | Evaluating Tumor Destruction or Reduction | 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Assessed for Safety and Tolerability | Open Label Treatment | 5 | participants | ||
| Evaluating Tumor Destruction or Reduction | Open Label Treatment | 5 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Squamous Carcinoma of Conjunctiva | 5 | |
| Overall Study | COMPLETED | Squamous Carcinoma of Conjunctiva | 3 | |
| Overall Study | NOT COMPLETED | Squamous Carcinoma of Conjunctiva | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Squamous Carcinoma of Conjunctiva | ||
| Total, other adverse events | Squamous Carcinoma of Conjunctiva | 0 | 5 |
| Total, serious adverse events | Squamous Carcinoma of Conjunctiva | 0 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22186988 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00456495
GET https://conductscience.org/api/trials/v1/NCT00456495/registered